Therapeutics News and Research

RSS

Decode Genetics announces Q2 2009 financials

deCODE genetics (Nasdaq: DCGN) today announced its consolidated financial results for the quarter ended June 30, 2009. A conference call to discuss these results and recent developments in the company's business will be webcast live tomorrow, Tuesday, August 11, at 8:00am Eastern Daylight Time/12 noon GMT/1pm British Summer Time (details below).

10 Aug 2009

Cytori Therapeutics Q2 2009 financial results

Total revenues were $8.5 million and $10.5 million for the three and six months ended June 30, 2009, respectively, compared to $1.4 million and $2.4 million for the same periods in 2008. As part of Cytori’s Olympus partnership, the Company recognized $7.3 million in development revenue in the second quarter of 2009, due mostly to the completion of enrollment in the cardiovascular disease clinical safety and feasibility studies.

From Evident Corporation - Life Sciences 10 Aug 2009

Expert available on recent FDA analysis of TNF blockers

Lloyd J. Old, M.D., is Director of the Ludwig Institute for Cancer Research (LICR) New York Branch. He is also Director of the Cancer Research Institute (CRI) Scientific Advisory Council, Director of the CRI/LICR Cancer Vaccine Collaborative, and Director of the CRI Cancer Vaccine Consortium. He has been a Member of the National Academy of Sciences since 1978.

9 Aug 2009

Scientists find key to strengthening immune response to chronic infection

A team of researchers from The Wistar Institute has identified a protein that could serve as a target for reprogramming immune system cells exhausted by exposure to chronic viral infection into more effective "soldiers" against certain viruses like HIV, hepatitis C, and hepatitis B, as well as some cancers, such as melanoma.

6 Aug 2009

Colon cancer may yield to cellular sugar starvation

Scientists at the Johns Hopkins Kimmel Cancer Center have discovered how two cancer-promoting genes enhance a tumor's capacity to grow and survive under conditions where normal cells die.

6 Aug 2009

Alnylam and Tekmira to collaborate on RNAi therapeutics

Alnylam Pharmaceuticals, Inc. and Tekmira Pharmaceuticals Corporation announced today that they will jointly participate in a new research collaboration focused on the discovery of novel cationic lipids and lipid nanoparticles for the systemic delivery of RNAi therapeutics.

6 Aug 2009

Innovative diabetes drug discovery partnership

The Juvenile Diabetes Research Foundation said today that it has entered into a novel collaborative research agreement with the Genomics Institute of the Novartis Research Foundation (GNF) to create a diabetes drug discovery and development platform.

5 Aug 2009

Aptamers offer unique therapeutic advantages

A novel class of drugs composed of single strands of DNA or RNA, called aptamers, can bind protein targets with a high strength and specificity and are currently in clinical development as treatments for a broad range of common diseases, as described in a comprehensive review article published online ahead of print in Oligonucleotides.

5 Aug 2009

Accelerating the development of new cancer drugs

A phase I clinical trial enrolled its first patient only two days after U.S. Food and Drug Administration clearance of the experimental drug for a first-in-human cancer trial, a milestone that normally takes three to six months. Investigators from The University of Texas M. D. Anderson Cancer Center and pharmaceutical company AstraZeneca have reported their work in the Journal of Clinical Oncology published online on August 3rd.

4 Aug 2009

Research points to new targets for melanoma

Recent research has uncovered an unexpected vulnerability in deadly melanoma cells that, when exploited, can cause the cancer cells to turn against themselves.

3 Aug 2009

Success of GERD therapy hinges on medication type and physician bedside manner

Patient satisfaction with their medications and the quality of interactions with their doctor reflect the success of gastroesophageal reflux disease (GERD) therapy, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.

3 Aug 2009

HIV/AIDS research initiative launched in South Africa

South Africa's Science and Technology Minister Naledi Pandor on Tuesday announced a government-sponsored research initiative that "aims to combat HIV and AIDS through scientific and technological research, the development of new drugs, diagnostic tests and vaccines," SAPA/IOL reports (7/28).

30 Jul 2009

Nanodiamonds hold promise for wound-healing applications

Bacterial infection is a major health threat to patients with severe burns and other kinds of serious wounds such as traumatic bone fractures. Recent studies have identified an important new weapon for fighting infection and healing wounds: insulin.

27 Jul 2009

Cytori Therapeutics comments on patent appeal

Cytori Therapeutics has been informed that the United States Federal Court in the Central District of California upheld a June 2008 decision relating to U.S. patent number 6,777,231 (the '231 patent).

26 Jul 2009

Nanoparticle antimicrobial gel formulation for topical use

Scientists in India are reporting successful laboratory tests of a new and potentially safer alternative to silver-based gels applied to the skin of burn patients to treat infections.

26 Jul 2009

Parabon NanoLabs awarded research grant to develop novel cancer therapeutics

Parabon NanoLabs, a leading designer and manufacturer of breakthrough products at the nanoscale, announced today its award of a National Science Foundation (NSF) Small Business Innovative Research (SBIR) grant.

21 Jul 2009

Targeted nanoparticles boost arsenic’s anticancer punch

Arsenic trioxide has a long history as a potent human poison, but it also has proven valuable as one of the primary treatment options for acute promyelocytic leukemia. Efforts to use arsenic trioxide to treat other types of cancer are under way, but clinical trials are revealing that the extreme toxicity of this material is likely to limit its utility as a broad-spectrum anticancer agent.

21 Jul 2009

Researchers decipher special role of the messenger Beta-interferon for immune responses

Researchers from the Molecular Immunology group at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany have now shown that Beta-Interferon also plays a crucial role during an immune response: without Beta-Interferon immune cells are unable to show "wanted posters" of pathogens to other cells.

20 Jul 2009

New discovery on DNA repair mechanism

Researchers at Washington University School of Medicine in St. Louis have shed new light on a process that fixes breaks in the genetic material of the body's cells. Their findings could lead to ways of enhancing chemotherapy drugs that destroy cancer cells by damaging their DNA.

17 Jul 2009

New drug blocks common cancer pathway

Scientists have developed a new drug which can reduce the growth of tumours in mice by up to 98 per cent, according to a study published in Molecular Cancer Therapeutics ** this week.

15 Jul 2009